News
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...
Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...
Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval ...
6d
MedPage Today on MSNGLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing MattersSAN FRANCISCO -- In order to maximize weight loss, a GLP-1 receptor agonist may be needed both before and after bariatric ...
3d
New Scientist on MSNYou don't need to take drugs like Ozempic consistently to lose weightPeople who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...
If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...
Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.
Dear J.H.: Metformin, a treatment for diabetes that works mostly by preventing the liver from making sugar, isn't new and has ...
With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...
Ozempic, a drug known for its physical health benefits, is now gaining recognition for its effectiveness in treating ...
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results